



# Active Ingredient Prescribing

List of Medicines for Brand Consideration

December 2022

Published by the Australian Commission on Safety and Quality in Health Care

Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600

Email: [mail@safetyandquality.gov.au](mailto:mail@safetyandquality.gov.au)

Website: [www.safetyandquality.gov.au](http://www.safetyandquality.gov.au)

ISBN: 978-1-922563-36-1

© Australian Commission on Safety and Quality in Health Care December 2022.

All material and work produced by the Australian Commission on Safety and Quality in Health Care is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Australian Commission on Safety and Quality in Health Care has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties, and where otherwise noted, all material presented in this publication is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Enquiries about the licence and any use of this publication are welcome and can be sent to [communications@safetyandquality.gov.au](mailto:communications@safetyandquality.gov.au).

This publication is uncontrolled when printed

The Commission's preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. Active ingredient prescribing – List of Medicines for Brand Consideration. Sydney: ACSQHC; 2022.

### **Disclaimer**

The content of this document is published in good faith by the Australian Commission on Safety and Quality in Health Care for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your health care provider on particular healthcare choices.

The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

# Contents

<b>Introduction</b>	<b>4</b>
<b>List of Medicines for Brand Consideration</b>	<b>5</b>
<b><u>A</u></b>	5
<b><u>B</u></b> (includes clostridium botulinum type A toxin and incobotulinum toxin A)	7
<b><u>C</u></b>	16
<b><u>D</u></b>	19
<b><u>E</u></b>	19
<b><u>F</u></b>	23
<b><u>H</u></b> (includes morphine hydrochloride trihydrate and morphine sulfate pentahydrate injections)	30
<b><u>I</u></b> (includes peginterferon beta-1a and peginterferon alfa-2a)	32
<b><u>L</u></b>	37
<b><u>M</u></b> (morphine hydrochloride trihydrate and morphine sulfate pentahydrate injections see p.31)	42
<b><u>O</u></b>	51
<b><u>P</u></b> (peginterferon beta-1a and peginterferon alfa-2a see p.34)	54
<b><u>Q</u></b>	56
<b><u>S</u></b>	57
<b><u>T</u></b>	60
<b><u>U</u></b>	62
<b><u>W</u></b>	63
<b><u>Z</u></b>	<b>Error! Bookmark not defined.</b>

This document was last updated by the Commission in December 2022.

From 1 January 2023, the Australian Government Department of Health and Aged Care is managing the curation of Active ingredient prescribing resources. From this date, please direct all AIP enquiries to [aiprescribing@health.gov.au](mailto:aiprescribing@health.gov.au)

## Introduction

In October 2019 the *National Health (Pharmaceutical Benefits) Amendment (Active Ingredient Prescribing) Regulations 2019*, and the *Veterans' Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019* mandated active ingredient prescribing.

Active ingredient prescribing uses standardised International Non-proprietary Names (INN) for medicines and will apply for most Pharmaceutical Benefits Scheme (PBS) / Repatriation Pharmaceutical Benefits Scheme (RPBS) items. From 1 February 2021 most prescriptions generated for supply under the PBS and the RPBS must meet the revised arrangements to be eligible for subsidy.

The Australian Commission on Safety and Quality in Health Care (the Commission) has been engaged by the Australian Government Department of Health and Aged Care (the Department) to generate and maintain the following active ingredient prescribing clinical support documents:

- [Active ingredient prescribing – User guide for Australian prescribers](#) (user guide)
- **List of Medicines for Brand Consideration** (LMBC)
- [List of Excluded Medicinal Items](#) (LEMI).

The *Active ingredient prescribing – User guide for Australian prescribers* supports prescribers to prescribe medicines by the active ingredient with best practice guidance for specification of brand. Principles are outlined in the user guide to determine when prescribers should consider brand name specification if clinically necessary. Specifying the brand name may be necessary to support safe and quality use of a medicine where consumer harm could result from switching between medicine brands or to ensure prescriber instructions are suitable for the dispensed medicine.

This **List of Medicines for Brand Consideration** includes medicines prescribers should consider prescribing by brand name, in addition to active ingredient name, if the inclusion of brand name is necessary for safe selection, or the clinical treatment of their patients. For example, in situations where formulations are not interchangeable due to variations in delivery of the active ingredient, prescribers should consider specification by brand for patient safety.

Clinical software systems will alert prescribers when a prescribed medicine is on the List of Medicines for Brand Consideration. The alert will advise the prescriber to consider what should be included on the prescription for patient safety. The alert will include a hyperlink to the List of Medicines for Brand Consideration giving prescribers easy access to the list. Prescribers will action an additional step either to read the list or ignore before prescribing a medicine on the List of Medicines for Brand Consideration.

The List of Medicines for Brand Consideration has been curated by the Commission, according to the principles in the user guide. The process was informed by the Commission's Active ingredient prescribing advisory group, in consultation with the Australian Government Department of Health and Aged Care and the Therapeutic Goods Administration. The List of Excluded Medicinal Items includes medicines and non-medicinal items which are exempt from active ingredient prescribing requirements. These items should be prescribed by brand only for practicality and safety purposes.

# List of Medicines for Brand Consideration

List of medicines prescribers should consider prescribing by brand name in addition to active ingredient name if the inclusion of brand name is necessary for the clinical treatment of their patients.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
adrenaline (epinephrine) 300 microgram/0.3 mL injection, pre-filled auto-inject pen device	Delivery device continuity required	EpiPen	<ul style="list-style-type: none"> <li>Adrenaline Mylan</li> <li>Anapen 300</li> <li>Adrenaline Viatris</li> </ul>	✓	✓	Patient familiarity with one brand is important for optimal emergency use
adrenaline (epinephrine) 150 microgram/0.3 mL injection, pre-filled auto-inject pen device	Delivery device continuity required	EpiPen Jr	<ul style="list-style-type: none"> <li>Adrenaline Jr Mylan</li> <li>Anapen 150</li> <li>Adrenaline Jr Viatris</li> </ul>	✓	✓	Patient familiarity with one brand is important for optimal emergency use
agalsidase alfa 3.5 mg/3.5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	Replagal	N/A	✗	N/A	–
agalsidase beta 35 mg injection	Similarity of active ingredient name and strength will likely cause confusion and selection errors	Fabrazyme	N/A	✗	N/A	–



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
amphotericin B (as liposomal) 50 mg powder for injection	Different formulations of the same active ingredient have different dosing and / or rates of administration	AmBisome amphotericin B ( <b>liposomal amphotericin</b> )	N/A	✗	N/A	These different formulations have the same chemical name, but different dosing and/or rates of administration
amphotericin B 50 mg powder for injection	Different formulations of the same active ingredient have different dosing and/or rates of administration	Amphotericin B Mylan (amphotericin B)	N/A	✗	N/A	<ul style="list-style-type: none"> <li>• These different formulations have the same chemical name, but different dosing and/or rates of administration</li> <li>• As of October 2021, Amphotericin B Mylan is no longer registered on the ARTG. However, Amphotericin B Mylan will be retained on the LMBC for reference.</li> </ul>
antithymocyte immunoglobulin equine 250 mg/5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	Atgam	N/A	✗	N/A	–
antithymocyte immunoglobulin rabbit 25 mg powder for injection	Similarity of active ingredient names will likely cause confusion and selection errors	Thymoglobulin	N/A	✗	N/A	–
atropine sulfate monohydrate 0.01% eye drops	Different formulations of the same active ingredient have different dosing	Eikance	N/A	✗	N/A	Indicated to slow the progression of myopia in children aged 4 to 14 years.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
atropine sulfate monohydrate 1% eye drops	Different formulations of the same active ingredient have different dosing	aTROpt	Atropine Sulphate Minims	✓	✗	-
beclometasone dipropionate 50 microgram/actuation inhalation	Delivery device continuity required.  Different formulations of the same active ingredient have different dosing and/or rates of administration.	<ul style="list-style-type: none"> <li>• Qvar 50 Inhaler</li> <li>• Qvar 50 Autohaler</li> </ul>	N/A	✓	N/A	-
beclometasone dipropionate 50 microgram/actuation nasal spray	Different formulations of the same active ingredient have different dosing and/or rates of administration	Beconase Allergy and Hayfever	N/A	✗	N/A	Beconase Allergy & Hayfever {beclometasone dipropionate 0.5 mg/g (50 microgram per actuation)} nasal spray is available as a 'PHARMACY MEDICINE' (Schedule 2)
beclometasone dipropionate 100 microgram/actuation inhalation	Delivery device continuity required	<ul style="list-style-type: none"> <li>• Qvar 100 Inhaler</li> <li>• Qvar 100 Autohaler</li> </ul>	N/A	✓	N/A	-

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
betamethasone dipropionate 0.05% 'optimised vehicle' ointment	Different formulations of the same active ingredient have different release characteristics	Diprosone OV Ointment	N/A	×	N/A	–
betamethasone dipropionate 0.05% 'optimised vehicle' cream	Different formulations of the same active ingredient have different release characteristics	Diprosone OV Cream	N/A	×	N/A	–
bifidobacterium bifidum, bifidobacterium infantis and lactobacillus acidophilus	Different formulations of the same active ingredient have different dosing and/or rates of administration	Labinic Drops	N/A	×	×	<ul style="list-style-type: none"> <li>• For pre-term infants</li> <li>• Helps enhance/promote healthy digestive system function in formula fed healthy infants</li> <li>• Enhance/promote healthy digestion in formula fed healthy infants. Medicine unapproved by TGA, accessible through Special Access Scheme.</li> </ul>
bifidobacterium infantis and lactobacillus acidophilus	Different formulations of the same active ingredient have different dosing and/or rates of administration	Infloran	N/A	×	×	<ul style="list-style-type: none"> <li>• For pre-term infants</li> <li>• Helps enhance/promote healthy digestive system function in formula fed healthy infants</li> <li>• Enhance/promote healthy digestion in formula fed healthy infants</li> </ul>



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
bimatoprost 0.03% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Lumigan	<ul style="list-style-type: none"> <li>• Bimprozt</li> <li>• Bimtop</li> <li>• Apo-Bimatoprost</li> <li>• Bimatoprost Sandoz</li> </ul>	✓	✓	Treatment for glaucoma – ‘a’ flagging across all brands
bimatoprost 0.03% eye drops, unit dose	Similarity of active ingredient names will likely cause confusion and selection errors	Lumigan PF	N/A	✓	N/A	Treatment for glaucoma. The ‘PF’ formulation indicates ‘preservative free’ and is available in single use dose units.
bimatoprost 0.03% + timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Ganfort 0.3/5	N/A	✓	N/A	Treatment for glaucoma
bimatoprost 0.03% + timolol 0.5% eye drops, unit dose	Similarity of active ingredient names will likely cause confusion and selection errors	Ganfort PF 0.3/5	N/A	✓	N/A	Treatment for glaucoma. The ‘PF’ formulation indicates ‘preservative free’ and is available in single use dose units.

<b>botulinum toxin type A</b>	Different brands of the same active ingredient have different dosing regimens for the same indications	Botox	N/A			<p><b>SPECIAL WARNINGS AND PRECAUTIONS FOR USE: Lack of interchangeability between botulinum toxin products – DUE TO THE LACK OF AN INTERNATIONAL UNIT, BOTOX® IS NOT THERAPEUTICALLY EQUIVALENT TO ANY OTHER BOTULINUM TOXIN TYPE A PREPARATIONS. THE POTENCIES OF BOTOX® AND OTHER BOTULINUM TOXIN TYPE A PREPARATIONS ARE BASED ON DIFFERENT ASSAY METHODS. IN VIEW OF THIS LACK OF HARMONISATION OF UNIT SYSTEMS FOR BOTULINUM TOXIN TYPE A, EXTREME CAUTION IS REQUIRED IF IT SHOULD PROVE NECESSARY TO SUBSTITUTE THE BOTULINUM TYPE A TOXIN OF ONE PHARMACEUTICAL COMPANY BY ANOTHER. THE EFFECT OF ADMINISTERING DIFFERENT BOTULINUM NEUROTOXIN SEROTYPES AT THE SAME TIME OR WITHIN SEVERAL MONTHS OF EACH OTHER IS UNKNOWN. EXCESSIVE NEUROMUSCULAR WEAKNESS MAY BE EXACERBATED BY ADMINISTRATION OF ANOTHER BOTULINUM TOXIN PRIOR TO THE RESOLUTION OF THE EFFECTS OF A PREVIOUSLY ADMINISTERED BOTULINUM TOXIN.</b></p> <p>Different brands have different dose regimens for the same indications.</p> <p>Different administration (subcutaneous or intradermal), different dose regimens for the different indications.</p>
-------------------------------	--	-------	-----	---	---	--

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
clostridium <b>botulinum type A toxin</b> – haemagglutinin complex	Different brands of the same active ingredient have different dosing regimens for the same indications	Dysport	N/A	✓	✗	Different brands have different dose regimens for the same indications.  <b>Caution: One Ipsen Unit is not equivalent to One Unit of any other botulinum toxin preparation.</b>
<b>incobotulinum toxin A</b>	Different brands of the same active ingredient have different dosing regimens for the same indications	Xeomin	N/A	✓	✗	Different brands have different dose regimens for the same indications.  <b>Caution: Unit doses recommended for Xeomin are not interchangeable with those for other preparations of botulinum toxin.</b>
brinzolamide 1% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	aZopt	BrinzoQuin	✓	✓	Treatment for glaucoma – ‘a’ flagging across all brands. Brand premium applies to originator brand.
brinzolamide 1% + brimonidine tartrate 0.2% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Simbrinza 1%/0.2%	N/A	✓	N/A	Treatment for glaucoma
brinzolamide 1% + timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Azarga	N/A	✓	N/A	Treatment for glaucoma

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
brimonidine tartrate 0.2% + timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Combigan	N/A	✓	N/A	Treatment for glaucoma
brimonidine tartrate 0.15% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Alphagan P 1.5	N/A	✓	N/A	Treatment for glaucoma
brimonidine tartrate 0.2% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Alphagan	Enidin	✓	✓	Treatment for glaucoma – ‘a’ flagging across all brands. Brand premium applies to originator brand.
buDESONide 200 microgram/ actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/ actuation inhalation (pressurised metered dose inhaler)	Different formulations of the same active ingredients in the same have different dosing and / or rates of administration. Delivery device continuity required	Symbicort Rapihaler 200/6	N/A	✓	✗	Treatment of Asthma

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
buDESONide 200 microgram/ actuation + formoterol (eformoterol) fumarate dihydrate 6 microgram/ actuation powder for inhalation (dry powder inhaler)	Different formulations of the same active ingredients in the same have different dosing and / or rates of administration. Delivery device continuity required	Symbicort Turbuhaler 200/6	<ul style="list-style-type: none"> <li>• BiResp Spiromax 200/6</li> <li>• DuoResp Spiromax 200/6</li> </ul>	✓	✓	Treatment of asthma
buDESONide 3 mg enteric capsule	Different formulations of the same active ingredient have different dosing and / or rates of administration. Different brands are not therapeutically equivalent	Budenofalk	N/A	✓	N/A	<ul style="list-style-type: none"> <li>• Budenofalk and Entocort have not been assessed as being therapeutically equivalent and similar dose forms are a potential source of confusion</li> <li>• Budenofalk may be more specifically targeted and provide greater coverage in the distal small intestine, resulting in a higher buDESONide concentration in the ileocecal region from Budenofalk compared with Entocort</li> </ul>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
buDESONide 3 mg modified release capsule	Different formulations of the same active ingredient have different dosing and / or rates of administration. Different brands are not therapeutically equivalent	Entocort	N/A	✗	N/A	Budenofalk and Entocort have not been assessed as being therapeutically equivalent and similar dose forms are a potential source of confusion
buprenorphine sublingual tablet; available in 200 microgram, 400 microgram, 2 mg and 8 mg strengths	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – <b>High-risk medicine (opioid)</b>	<b>Subutex</b>	<ul style="list-style-type: none"> <li>• <b>Temgesic</b></li> <li>• <b>Bupradex</b></li> </ul>	✓	✗	<ul style="list-style-type: none"> <li>• Subutex sublingual tablet for opiate dependence is PBS listed</li> <li>• Subutex and Bupradex available in 400 microgram, 2 mg and 8 mg strengths</li> <li>• Temgesic available in 200 microgram strength</li> </ul>
buprenorphine modified release injection; available in 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL, 32 mg/0.64 mL, 64 mg/0.18 mL, 96 mg/0.27 mL, 128 mg/0.36 mL and 160 mg/0.45 mL injection strengths	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – <b>High-risk medicine (opioid)</b>	<ul style="list-style-type: none"> <li>• <b>Buvidal Weekly;</b> available in 8 mg, 16 mg, 24 mg or 32 mg strengths</li> <li>• <b>Buvidal Monthly;</b> available in 64 mg, 96 mg, 128 mg or 160 mg strengths</li> </ul>	N/A	✓	✗	<ul style="list-style-type: none"> <li>• Buvidal modified release injection comes in different strengths</li> <li>• Available on PBS in 8 mg, 16 mg 24 mg or 32 mg strengths for weekly injection</li> <li>• Available on PBS in 64 mg, 96 mg, 128 mg strengths for monthly injection</li> <li>• PBS listed for opiate dependence, except for 160 mg strength injection</li> </ul>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
buprenorphine modified release injection; available in 100 mg/0.5 mL injection and 300 mg/1.5 mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – <b>High-risk medicine (opioid)</b>	<b>Sublocade</b>	N/A	✓	✗	Sublocade comes in 100 mg/0.5 mL and 300 mg/1.5 mL strengths indicated for opiate dependence.  <b>Caution: High dose modified release Sublocade 300 mg/1.5 mL injection should be prescribed by brand.</b>
buprenorphine + naloxone sublingual film; available in 2 mg/500 microgram and 8 mg/2 mg strengths	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – <b>High-risk medicine (opioid)</b>	<ul style="list-style-type: none"> <li>• <b>Suboxone</b> Film 2/0.5</li> <li>• <b>Suboxone</b> Film 8/2</li> </ul>	N/A	✓	N/A	For opiate dependence
buprenorphine + naloxone sublingual tablet; available in 2 mg/500 microgram and 8 mg/2 mg strengths	Different brands of the same active ingredient have different dosing regimens for the same indications – <b>High-risk medicine (opioid)</b>	<ul style="list-style-type: none"> <li>• <b>Bupradone</b> 2/0.5</li> <li>• <b>Bupradone</b> 8/2</li> </ul>	N/A	✗	✗	For opiate dependence

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
buprenorphine + naloxone sublingual tablet; available in 0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8.6 mg/2.1 mg and 11.4 mg/2.9 mg strengths	Different brands of the same active ingredient have different dosing regimens for the same indications – <b>High-risk medicine (opioid)</b>	<ul style="list-style-type: none"> <li>• <b>Zubsolv</b> 0.7/0.18</li> <li>• <b>Zubsolv</b> 1.4/0.36</li> <li>• <b>Zubsolv</b> 2.9/0.71</li> <li>• <b>Zubsolv</b> 5.7/1.4</li> <li>• <b>Zubsolv</b> 8.6/2.1</li> <li>• <b>Zubsolv</b> 11.4/2.9</li> </ul>	N/A	✗	✗	For opiate dependence.  As of October 2022, Zubsolv is no longer registered on the ARTG. However, Zubsolv will be retained on the LMBC for reference.
buprenorphine (transdermal) patch; available in 5 microgram/hour, 10 microgram/hour, 15 microgram/hour, 20 microgram/hour, 25 microgram/hour, 30 microgram/hour and 40 microgram/hour	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – <b>High-risk medicine (opioid)</b>	Norspan	<ul style="list-style-type: none"> <li>• Buprenorphine Sandoz</li> <li>• Bupredermal</li> </ul>	✓	✓	<ul style="list-style-type: none"> <li>• PBS listings for chronic severe disabling pain unresponsive to non-opioid analgesics, and / or for chronic severe disabling pain in patients receiving palliative care</li> <li>• At strengths from 5 microgram/hour to 15 microgram/hour the PBS listed brands Norspan, Bupredermal, and Buprenorphine Sandoz are 'a' flagged</li> </ul>
C1 esterase inhibitor 500 units injection [1 vial] (& inert substance diluent [10 mL vial])	Different brands of the same active ingredient have different dosing regimens for different approved indications. Different brands are not assessed as therapeutically equivalent	Berinert IV	N/A	✗	N/A	Treatment of acute attacks of hereditary angioedema (HAE)



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
C1 esterase inhibitor 500 units injection [2 vials] (&) inert substance diluent [2 × 5 mL vials]	Different brands of the same active ingredient have different dosing regimens for different approved indications. Different brands are not assessed as therapeutically equivalent	Cinryze	N/A	✗	N/A	<ul style="list-style-type: none"> <li>• Treatment and pre-procedure prevention of angioedema attacks in those with C1 inhibitor deficiency.</li> <li>• Routine prevention of angioedema attacks for those with frequent attacks of HAE, who are intolerant to or insufficiently protected by oral therapy</li> </ul>
CARBAMazepine 200 mg tablet	Narrow therapeutic index (anti-epileptic)	tEGRETOI 200	<ul style="list-style-type: none"> <li>• CARBAMazepine Sandoz</li> <li>• Teril</li> </ul>	✓	✓	<ul style="list-style-type: none"> <li>• When prescribing CARBAMazepine 200 mg specify by brand to eliminate confusion between immediate release tablet and modified release tablet</li> <li>• Teril is not PBS listed</li> </ul>
CARBAMazepine 200 mg modified release tablet	Narrow therapeutic index (anti-epileptic)	tEGRETOI CR 200	N/A	✓	✗	When prescribing CARBAMazepine 200 mg specify by brand to eliminate confusion between immediate release tablet and modified release tablet
ciclosPORIN 10 mg capsule	Narrow therapeutic index (for certain indications)	NEOral 10	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
ciclosPORIN capsule; available in 25 mg, 50 mg and 100 mg strengths	Narrow therapeutic index (for certain indications)	<ul style="list-style-type: none"> <li>• NEOral 25</li> <li>• NEOral 50</li> <li>• NEOral 100</li> </ul>	<ul style="list-style-type: none"> <li>• ciclosPORIN Sandoz</li> <li>• APO-ciclosPORIN</li> </ul>	✓	✓	CiclosPORIN must be prescribed and dispensed by brand name. Patients should be stabilised on a particular brand of oral ciclosPORIN because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosPORIN concentration. Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist.
ciclosPORIN 100 mg/mL oral liquid	Narrow therapeutic index (for certain indications)	NEOral	N/A	✓	N/A	–
ciclosPORIN 50 mg/mL injection	Narrow therapeutic index (for certain indications)	Sandimmun	N/A	✓	N/A	–
clozapine 50 mg tablet, clozapine 200 mg tablet	Narrow therapeutic index / <b>Highly Specialised Drug</b> (Section 100 HSD)	<ul style="list-style-type: none"> <li>• Clopine 50</li> <li>• Clopine 200</li> </ul>	Clozitor	✓	✓	Used to treat schizophrenia. Different brands are not a' flagged on the PBS. The specific brand patient monitoring system is Clopine Central™ for Clopine®.
clozapine 25 mg tablet, clozapine 100 mg tablet	Narrow therapeutic index / <b>Highly Specialised Drug</b> (Section 100 HSD)	<ul style="list-style-type: none"> <li>• Clozaril 25</li> <li>• Clozaril 100</li> </ul>	<ul style="list-style-type: none"> <li>• Clopine 25</li> <li>• Clopine 100</li> <li>• Clozitor</li> </ul>	✓	✓	Used to treat schizophrenia. Different brands are not a' flagged on the PBS. The specific brand patient monitoring system is Clozaril Patient Monitoring System (CPMS) for Clozaril® and Clopine Central™ for Clopine®.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
clozapine 50 mg/mL oral liquid	Narrow therapeutic index / <b>Highly Specialised Drug</b> (Section 100 HSD)	Clopine Suspension	Versacloz	✓	✓	The brands Versacloz and Clopine are not 'a' flagged on the PBS. <b>Caution: Versacloz is not listed on the ARTG.</b>
dorzolamide 2% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Trusopt	Trusamide	✓	✓	Treatment for glaucoma – 'a' flagging across all brands
dorzolamide 2% + timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Cosopt	<ul style="list-style-type: none"> <li>Cosdor</li> <li>Dorzolamide/Timolol Juno 20/5</li> </ul>	✓	✓	<ul style="list-style-type: none"> <li>Treatment for glaucoma – 'a' flagging across all brands. Brand premium applies to originator brand.</li> <li>Dorzolamide/Timolol Juno 20/5 is not PBS listed</li> </ul>
epoetin lambda injection; available in 1,000 units/0.5 mL, 2,000 units/0.5 mL, 3,000 units/0.3 mL, 4,000 units/0.4 mL, 5,000 units/0.5 mL, 6,000 units/0.6 mL, 8,000 units/0.8 mL, 10,000 units/mL, 20,000 units/0.5 mL and 40,000 units/mL injection strengths	Similarity of active ingredient names will likely cause confusion and selection errors	Eprex	N/A	✓	N/A	Similar names as well as similar looking strengths are a potential source of confusion

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
epoetin beta injection; available in 2,000 units/0.3 mL, 3,000 units/0.3 mL, 4,000 units/0.3 mL, 5,000 units/0.3 mL, 6,000 units/0.3 mL and 10,000 units/0.6 mL injection strengths	Similarity of active ingredient names will likely cause confusion and selection errors	NeoRecormon	N/A	✓	N/A	–
epoetin lambda injection; available in 1,000 units/0.5 mL, 2,000 units/mL, 3,000 units/0.3 mL, 4,000 units/0.4 mL, 5,000 units/0.5 mL, 6,000 units/0.6 mL, 8,000 units/0.8 mL and 10,000 units/mL injection strengths	Similarity of active ingredient names will likely cause confusion and selection errors	Novicrit	N/A	✓	N/A	–
estradiol 1 mg tablet [14] (& estradiol 1 mg + dydrogesterone 10 mg tablet [14])	Similarity of active ingredient names will likely cause confusion and selection errors	Femoston 1/10	N/A	✓	N/A	–
estradiol 2 mg tablet [14] (& estradiol 2 mg + dydrogesterone 10 mg tablet [14])	Similarity of active ingredient names will likely cause confusion and selection errors	Femoston 2/10	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
estradiol transdermal patches; available in 25 microgram/ 24 hours patch, 50 microgram/ 24 hours patch, 75 microgram/ 24 hours patch and 100 microgram/ 24 hours patch	Different brands of the same active ingredient have different dosing regimens for the same indications	Climara (used once a week)	N/A	✓	N/A	<b>Caution: specify by brand to avoid confusion with different dosing frequency</b>
estradiol transdermal patches; available in 25 microgram/ 24 hours patch, 37.5 microgram/ 24 hours patch, 50 microgram/ 24 hours patch, 75 microgram/ 24 hours patch and 100 microgram/ 24 hours patch	Different brands of the same active ingredient have different dosing regimens for the same indications	Estraderm MX (used twice a week)	Estradot (used twice a week)	✓	✓	No 'a' flagging across brands. <b>Caution: specify by brand to avoid confusion with different dosing frequency.</b>
estradiol 50 microgram/ 24 hours patch [4] (& estradiol 50 microgram/ 24 hours + norethisterone acetate 140 microgram/ 24 hours patch [4])	Similarity of active ingredient names will likely cause confusion and selection errors	Estalis sequi 50/140	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
estradiol 50 microgram/ 24 hours patch [4] (& estradiol 50 microgram/ 24 hours + norethisterone acetate 250 microgram/ 24 hours patch [4])	Similarity of active ingredient names will likely cause confusion and selection errors	Estalis sequi 50/250	N/A	✓	N/A	–
everolimus tablet; available in 250 microgram, 500 microgram, 750 microgram and 1 mg strengths	Narrow therapeutic index	Cetican	Everocan	✓	✓	Indicated for renal allograft rejection
everolimus tablet; available in 2.5 mg, 5 mg and 10 mg strengths	Narrow therapeutic index. Different brands have different dosing regimens for different approved indications	Afinitor	Everolimus Sandoz; available in 5 mg and 10 mg strengths	✓	✓	Indicated for tuberous sclerosis complex (TSC), Metastatic or un-resectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET ) and stage IV clear cell variant renal cell carcinoma (RCC)
everolimus dispersible tablet; available in 2 mg, 3 mg and 5 mg strengths	Narrow therapeutic index. Different brands have different dosing regimens for different approved indications	Afinitor dispersible	N/A	✓	N/A	<ul style="list-style-type: none"> <li>Indicated for refractory seizures associated with TSC</li> <li>The dispersible tablets are not interchangeable with the regular tablets as they have a lower bioavailability. Switching formulations should only be done under specialist advice, with therapeutic drug monitoring (TDM) required.</li> </ul>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
fentanyl lozenge; available in 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1200 microgram and 1600 microgram	Narrow therapeutic index – <b>High-risk medicine (opioid analgesic)</b>	Actiq	N/A	✓	N/A	–
fentanyl orally disintegrating tablet; available in 100 microgram, 200 microgram, 400 microgram, 600 microgram and 800 microgram	Narrow therapeutic index – <b>High-risk medicine (opioid analgesic)</b>	Fentora	N/A	✓	N/A	–
fentanyl sublingual tablet; available in 100 microgram, 200 microgram, 300 microgram, 400 microgram, 600 microgram and 800 microgram	Narrow therapeutic index – <b>High-risk medicine (opioid analgesic)</b>	Abstral	N/A	✓	N/A	–
fentanyl (as fentanyl citrate) 100 microgram or 400 microgram per actuation nasal spray solution with metered dose pump	Narrow therapeutic index – <b>High-risk medicine (opioid analgesic)</b>	Pecfent	N/A	✗	N/A	As of October 2021, Pecfent is no longer registered on the ARTG. However, Pecfent will be retained on the LMBC for reference.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
fentanyl patches; available in 12 microgram/hour, 25 microgram/hour, 50 microgram/hour and 100 microgram/hour	Narrow therapeutic index – <b>High-risk medicine (opioid)</b>	Durogesic	<ul style="list-style-type: none"> <li>• Denpax</li> <li>• Dutran</li> <li>• Fenpatch</li> <li>• Fentanyl Sandoz</li> <li>• APO-Fentanyl</li> </ul>	✓	✓	Fentanyl patches are available as matrix* and reservoir formulations. Reservoir patches must not be cut because damage to the rate-limiting membrane can lead to rapid release of fentanyl resulting in overdose. Risk of abuse with reservoir patches. <b>Caution: PATCHES SHOULD NOT BE CUT NOR DIVIDED. DAMAGED PATCHES SHOULD NOT BE USED AS IT USES DRUG-IN-ADHESIVE RESERVOIR TECHNOLOGY.</b>
fluorometholone 0.1% eye drops	Similarity of active ingredient name and strength will likely cause confusion and selection errors	FML Liquifilm	N/A	✗	N/A	–
fluorometholone acetate 0.1% eye drops	Similarity of active ingredient name and strength will likely cause confusion and selection errors	Flarex	N/A	✗	N/A	Not interchangeable with fluorometholone 0.1% eye drops as the acetate formulation makes the drug more lipophilic, facilitating better penetration into the ocular surface and providing greater anti-inflammatory efficacy in the eye



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
flupentixol decanoate 20 mg/mL injection	Different formulation release characteristics – <b>High-risk medicine (antipsychotic)</b>	Fluanxol Depot	N/A	✓	N/A	Fluanxol (flupentixol decanoate) is not intended for short-term therapy (less than 3 months) and is administered by intramuscular injection, in the gluteus maximus. <b>Fluanxol is NOT for intravenous use. Caution: specify by brand to avoid confusion between different strength depot injections.</b>
flupentixol decanoate 100 mg/mL injection	Different formulation release characteristics – <b>High-risk medicine (antipsychotic)</b>	Fluanxol Concentrated Depot	N/A	✓	N/A	<b>Caution: Doses greater than 100 mg/fortnight are usually not deemed necessary although higher doses have been used occasionally in some treatment-resistant patients. Patients who require higher doses of Fluanxol Depot to control symptoms of schizophrenia and / or those who complain of discomfort with a large injection volume may be administered Fluanxol Concentrated Depot (100 mg/mL) in preference to Fluanxol Depot (20 mg/mL).</b>
fluticasone propionate powder for inhalation; available in 100 microgram/actuation, 250 microgram/actuation and 500 microgram/actuation strengths	Similarity of active ingredient names will likely cause confusion and mix-ups	<ul style="list-style-type: none"> <li>Flixotide Junior Accuhaler (100 microgram/actuation)</li> <li>Flixotide Accuhaler (250 microgram/actuation or 500 microgram/actuation)</li> </ul>	<ul style="list-style-type: none"> <li>Axotide Junior Accuhaler (100 microgram/actuation)</li> <li>Axotide Accuhaler (250 microgram/actuation)</li> </ul>	✓	✓	Inhalation devices – may not be interchangeable

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
fluticasone furoate powder for inhalation; available in 100 microgram / actuation and 200 microgram / actuation strengths	Similarity of active ingredient names will likely cause confusion and mix-ups	Arnuity Ellipta	N/A	✓	N/A	Inhalation devices – may not be interchangeable
follitropin alfa 300 units (22 microgram)/ 0.5 mL injection	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Bemfola	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.
follitropin alfa 300 units (21.84 microgram)/ 0.5 mL injection	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Gonal-F Pen	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
follitropin alfa 300 units (21.84 microgram)/ 0.5 mL cartridge	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Ovaleap	N/A	✓	N/A	<ul style="list-style-type: none"> <li>Ovaleap is a cartridge for use with an Ovaleap pen</li> <li>Patient familiarity with one brand is important, as instructions for use vary between preparations. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.</li> </ul>
follitropin alfa 450 units (33 microgram)/ 0.75 mL injection	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Bemfola	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.
follitropin alfa 450 units (32.76 microgram)/ 0.75 mL injection	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Gonal-F Pen	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
follitropin alfa 450 units (32.76 microgram)/ 0.75 mL cartridge	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Ovaleap	N/A	✓	N/A	<ul style="list-style-type: none"> <li>Ovaleap is a cartridge for use with an Ovaleap pen</li> <li>Patient familiarity with one brand is important, as instructions for use vary between preparations. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.</li> </ul>
follitropin alfa 900 units (65.52 microgram)/ 1.5 mL injection	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Gonal-F Pen	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
follitropin alfa 900 units (65.52 microgram)/ 1.5 mL cartridge	Different formulations of the same biosimilar active ingredient have different dosing and / or rates of administration. Delivery device continuity required	Ovaleap	N/A	✓	N/A	<ul style="list-style-type: none"> <li>Ovaleap is a cartridge for use with an Ovaleap pen</li> <li>Patient familiarity with one brand is important, as instructions for use vary between preparations. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.</li> </ul>
formoterol fumarate dihydrate 12 microgram/ actuation powder for inhalation	Administration delivery devices have different instructions for use and consumer familiarity with one product is an important contributor to consumer compliance and safety	Foradile 12 microgram powder for inhalation, 60 capsules used with Aerolizer inhalation device	N/A	✓	N/A	Dry powder devices – may not be interchangeable

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
formoterol fumarate dihydrate 12 microgram/ actuation powder for inhalation	Administration delivery devices have different instructions for use and consumer familiarity with one product is an important contributor to consumer compliance and safety	Oxis Turbuhaler 12 microgram/ actuation powder for inhalation, 60 actuations used with Turbuhaler inhalation device	N/A	✓	N/A	Dry powder devices – may not be interchangeable
HYDROMorphone hydrochloride tablet; available in 4 mg and 8 mg strengths	Different formulation release characteristics – <b>High-risk medicine (opioid analgesic)</b>	dilaUDID	N/A	✓	N/A	<b>Caution: Specify brand for immediate release formulation of high-risk medicine (opioid analgesic)</b>
HYDROMorphone hydrochloride modified release tablet; available in 4 mg and 8 mg strengths	Different formulation release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Jurnista	N/A	✓	N/A	<b>Caution: Specify brand for modified release formulation of high-risk medicine (opioid analgesic)</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
<b>HYDROmorphine hydrochloride</b> 10 mg/mL injection	Similarity of active ingredient names will likely cause confusion and mix-ups – <b>High-risk medicine (opioid analgesic)</b>	dilaUDID-HP 10 mg/mL injection	<ul style="list-style-type: none"> <li>•HYDROmorphine Juno-HP</li> <li>•Medsurge HYDROmorphine 10 mg/1 mL</li> </ul>	✓	✓	<b>Caution: Specify by brand to avoid confusion with morphine salts in 10 mg/mL injections</b>
<b>morphine hydrochloride trihydrate</b> 10 mg/mL injection	Similarity of active ingredient names will likely cause confusion and mix-ups – <b>High-risk medicine (opioid analgesic)</b>	Morphine Juno 10 mg/mL	N/A	✓	N/A	<b>Caution: specify by brand to avoid confusion with other morphine salts and HYDROmorphine in 10 mg/mL injections</b>
<b>morphine sulfate pentahydrate</b> 10 mg/mL injection	Similarity of active ingredient names will likely cause confusion and mix-ups – <b>High-risk medicine (opioid analgesic)</b>	Morphine Sulfate 10 mg/1 mL Medsurge	<ul style="list-style-type: none"> <li>• DBL Morphine Sulfate Pentahydrate</li> </ul>	✓	✓	<b>Caution: specify by brand to avoid confusion with other morphine salts and HYDROmorphine in 10 mg/mL injections</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
Insulin <b>(all insulin products)</b>	Narrow therapeutic index – <b>High-risk medicine (insulin)</b> .  Different formulations of the same active ingredient have dosing. Delivery device continuity required	There are many insulin products that include the same, or very similar, active ingredient names which could lead to prescribing, dispensing and administration errors	–	–	–	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different. User training is required. Where there are many preparations that include the same, or very similar, generic name which could lead to prescribing, dispensing and administration errors.
insulin glargine	Narrow therapeutic index – <b>High-risk medicine (insulin) – regular dose</b>  Different formulations of the same active ingredient have dosing. Delivery device continuity required	Optisulin Solostar 100 units/mL injection	Semglee 100 units/mL injection	✓	N/A	Optisulin brand and Semglee brand are available in 100 units/mL injection. Toujeo brand are available in 300 units/mL injection. The dispensing pens are different. The different brands have different dose regimens. The generic/biosimilar brand of insulin glargine 100 units/mL injection is ‘a’ flagged with Optisulin brand.



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
insulin glargine	<p>Narrow therapeutic index – <b>High-risk medicine (insulin) – high dose.</b></p> <p>Different formulations of the same active ingredient have dosing. Delivery device continuity required</p>	Toujeo Solostar 300 units/mL injection	N/A	✓	N/A	Toujeo brand is available in 300 units/mL injection, Optisulin Solostar brand and the Semglee brand are available in 100 units/mL injection. The dispensing pens are different. Different brands have different dose regimens. <b>Caution: specify by brand to avoid supply of incorrect strength of insulin glargine.</b>
insulin aspart	<p>Narrow therapeutic index – <b>High-risk medicine (insulin) – fast acting</b></p> <p>Different formulations of the same active ingredient have dosing. Delivery device continuity required</p>	Fiasp FlexTouch 100 units/mL <b>fast acting injection</b>	N/A	✓	N/A	Fiasp is an ultra-fast acting insulin for subcutaneous administration. Fiasp administered 0–2 minutes before the start of a meal produced a significantly greater post-meal glucose lowering effect after a standardised meal test compared to NovoRapid. Administration of Fiasp up to 20 minutes after starting a meal was as efficacious as NovoRapid given before a meal.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
insulin aspart	Narrow therapeutic index – <b>High-risk medicine (insulin)</b>  Different formulations of the same active ingredient have dosing. Delivery device continuity required	NovoRapid Penfill and FlexPen 100 units/mL injection	Truvelog and Truvelog Solostar 100 units/mL injection	✓	✗	NovoRapid has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, insulin aspart products should generally be given immediately before a meal or when necessary, soon after the start of a meal.
interferon beta-1a 6 million units (30 microgram)/ 0.5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	<b>Avonex</b>	N/A	✓	N/A	No 'a' flagging across brands
interferon beta-1a 12 million units (44 microgram)/ 0.5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	<ul style="list-style-type: none"> <li>• <b>Rebif 44 pen devices</b></li> <li>• <b>Rebif 44 syringes</b></li> </ul>	N/A	✓	N/A	No 'a' flagging across brands
peginterferon beta-1a; available in a Titration pack (63 microgram/0.5 mL injection and 94 microgram/0.5 mL injection) and in a 125 microgram/0.5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	Plegridy	N/A	✓	N/A	Potential for pegylated interferon to be confused with interferon products

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
peginterferon alfa-2a injection; available in 135 microgram/0.5 mL injection and 180 microgram/0.5 mL injection strengths	Similarity of active ingredient names will likely cause confusion and selection errors	Pegasys	N/A	✓	N/A	–
iron (as ferric carboxymaltose) injection; available in 100 mg/2 mL injection, 500 mg/10 mL injection and 1 g/20 mL injection strengths	Different brands of the same active ingredient have different dosing regimens for the same indications. Similarity of active ingredient names will likely cause confusion and selection errors	Ferinject	N/A	✓	N/A	Dose administered by intravenous injection or infusion
iron (as ferric derisomaltose) injection; available in 500 mg/5 mL injection and 1 g/10 mL injection strengths	Different brands of the same active ingredient have different dosing regimens for the same indications. Similarity of active ingredient names will likely cause confusion and selection errors	Monofer	N/A	✓	N/A	Dose administered by intravenous injection or infusion

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
iron (as polymaltose) 100 mg/2 mL injection	Different brands of the same active ingredient have different dosing regimens for the same indications. Similarity of active ingredient names will likely cause confusion and selection errors	Ferrosig	N/A	✓	N/A	Dose administered by intramuscular injection or intravenous infusion
iron (as sucrose) 100 mg/5 mL injection	Different brands of the same active ingredient have different dosing regimens for the same indications. Similarity of active ingredient names will likely cause confusion and selection errors	Venofer	N/A	✓	N/A	Dose administered by intravenous infusion
itraconazole 50 mg capsule	Different brands of the same active ingredient have different dosing regimens for the same indications	Lozanoc	N/A	✓	N/A	Can be given with or without food. This preparation is not interchangeable with other itraconazole preparations.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
itraconazole 100 mg capsule	Different brands of the same active ingredient have different dosing regimens for the same indications	Sporanox	<ul style="list-style-type: none"> <li>• Itracap</li> <li>• Itranox</li> <li>• APO- Itraconazole</li> </ul>	✓	✓	Must be taken with food. This preparation is not interchangeable with other itraconazole preparations.
latanoprost 0.005% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	xalaTAN	<ul style="list-style-type: none"> <li>• Xalaprost</li> <li>• APO- Latanoprost</li> <li>• Latanoprost Sandoz</li> </ul>	✓	✓	Treatment for glaucoma – ‘a’ flagging across all brands
latanoprost 0.005% + timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	xalaCOM	<ul style="list-style-type: none"> <li>• Xalamol 50 / 5</li> <li>• APO- Latanoprost / Timolol 0.05 / 5</li> </ul>	✓	✓	Treatment for glaucoma – ‘a’ flagging across all brands
leuprorelin acetate 7.5 mg modified release injection [1 chamber] (& inert substance diluent [1 mL chamber], 1 dual chamber syringe	Different formulations of the same active ingredient have different dosing route of administration. Delivery device continuity required.	<b>Lucrin Depot 7.5 mg PDS</b>	N/A	✓	N/A	Lucrin is administered by intramuscular injection

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
leuprorelin acetate 7.5 mg modified release injection [1 syringe] (& inert substance diluent [1 syringe])	Different formulations of the same active ingredient have different dosing route of administration.  Delivery device continuity required	<b>Eligard 1 month</b>	N/A	✓	N/A	Eligard is administered by subcutaneous injection
leuprorelin acetate 22.5 mg modified release injection [1 chamber] (& inert substance diluent [1.5 mL chamber], 1 dual chamber syringe)	Different formulations of the same active ingredient have different dosing route of administration.  Delivery device continuity required	<b>Lucrin Depot 3 Month PDS</b>	N/A	✓	N/A	Lucrin is administered by intramuscular injection
leuprorelin acetate 22.5 mg modified release injection [1 syringe] (& inert substance diluent [1 syringe])	Different formulations of the same active ingredient have different dosing route of administration.  Delivery device continuity required	<b>Eligard 3 Month</b>	N/A	✓	N/A	Eligard is administered by subcutaneous injection

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
leuprorelin acetate 30 mg modified release injection [1 chamber] (& inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications.  Delivery device continuity required	<b>Lucrin Depot 4 Month PDS 30 mg</b>	N/A	✓	N/A	<ul style="list-style-type: none"> <li>• Lucrin Depot brand in this strength is indicated for locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate</li> <li>• Lucrin is administered by intramuscular injection</li> </ul>
leuprorelin acetate 30 mg modified release injection [1 chamber] (& inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications.  Delivery device continuity required	<b>Lucrin Depot Paediatric 30 mg PDS</b>	N/A	✓	N/A	<ul style="list-style-type: none"> <li>• <b>Specific brand for a specific indication</b> – Lucrin Depot Paediatric brand in this strength is for central precocious puberty</li> <li>• Lucrin is administered by intramuscular injection</li> </ul>
leuprorelin acetate 30 mg modified release injection [1 syringe] (& inert substance diluent [1 syringe]	Different brands of the same active ingredient have different dosing regimens for specific approved indications.  Delivery device continuity required.	<b>Eligard 4 month 30 mg</b>	N/A	✓	N/A	<ul style="list-style-type: none"> <li>• Eligard brand in this strength is indicated for locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate</li> <li>• Eligard is administered by subcutaneous injection</li> </ul>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
leuprorelin acetate 45 mg modified release injection [1 chamber] (& inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different formulations of the same active ingredient have different dosing route of administration.  Delivery device continuity required.	<b>Lucrin Depot 6 Month</b>	N/A	✓	N/A	Lucrin is administered by intramuscular injection
leuprorelin acetate 45 mg modified release injection [1 syringe] (& inert substance diluent [1 syringe]	Different formulations of the same active ingredient have different dosing route of administration.  Delivery device continuity required.	<b>Eligard 6 month</b>	N/A	✓	N/A	Eligard is administered by subcutaneous injection
levodopa + benserazide capsule; available in 50 mg/12.5 mg, 100 mg/25 mg and 200 mg/50 mg strengths	Different formulations of the same active ingredient have different release characteristics	<ul style="list-style-type: none"> <li>• <b>Madopar</b> 62.5 capsule</li> <li>• <b>Madopar</b> 125 capsule</li> <li>• <b>Madopar</b> capsule</li> </ul>	N/A	✓	N/A	–



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
levodopa + benserazide tablet; available in 100 mg/25 mg and 200 mg/50 mg strengths	Different formulations of the same active ingredient have different release characteristics	<ul style="list-style-type: none"> <li>• <b>Madopar</b> 125 tablet</li> <li>• <b>Madopar</b> tablet</li> </ul>	N/A	✓	N/A	–
levodopa + benserazide dispersible tablet; available in 50 mg/12.5 mg, and 100 mg/25 mg strength	Different formulations of the same active ingredient have different release characteristics.	<ul style="list-style-type: none"> <li>• <b>Madopar Rapid</b> 62.5 dispersible tablet</li> <li>• <b>Madopar Rapid</b> 125</li> </ul>	N/A	✓	N/A	–
levodopa + benserazide modified release capsule; available in 100 mg/25 mg strength	Different formulations of the same active ingredient have different release characteristics.	<b>Madopar HBS</b> modified release capsule	N/A	✓	N/A	–
levothyroxine sodium; available in 50 microgram, 75 microgram, 100 microgram and 200 microgram tablet	Narrow therapeutic index	Oroxine	<ul style="list-style-type: none"> <li>• Eutroxsig</li> <li>• Levoxine</li> </ul>	✓	✓	These brands are 'a' flagged at all PBS listed strengths. However, not interchangeable with Eltroxin brand.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
levothyroxine sodium; available in 50 microgram, 75 microgram, 100 microgram, 125 microgram and 200 microgram tablet	Narrow therapeutic index	Eltroxin	N/A	✓	N/A	<b>Caution: Eltroxin is not bioequivalent on a same-dose basis with Eutroxsig, Oroxin or Levoxine.</b> If a decision is made to switch a patient from Eutroxsig/Oroxine/Levoxine to Eltroxin, then prescribers should have a plan for monitoring TSH. Prescribers should be aware that dose adjustment may be required. Prescribers should tell their patients not to interchange Eltroxin and Eutroxsig/Oroxine/Levoxine unless a decision has been made to switch products, and there is a plan for monitoring TSH levels and review of dose.
lithium carbonate 250 mg tablet	Narrow therapeutic index	Lithicarb	N/A	✓	N/A	<b>Caution: Specify by brand to avoid supply of incorrect strength</b>
lithium carbonate 450 mg modified release tablet	Narrow therapeutic index	Quilonum SR	N/A	✓	N/A	<b>Caution: Specify by brand to avoid supply of incorrect strength</b>
mesalazine 250 mg enteric tablet	Different formulations of the same active ingredient have different release characteristics	Mesasal	N/A	✓	N/A	Treatment for ulcerative colitis and Crohn's disease. There is no 'a' or 'b' flagging across the different brands of enteric tablets including Mesasal, Salofalk and Asacol.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
mesalazine modified release tablet; available in 500 mg and 1 g strengths	Different formulations of the same active ingredient have different release characteristics	Pentasa	N/A	✓	N/A	Treatment for ulcerative colitis and Crohn's disease
mesalazine enteric tablet; available in 500 mg and 1 g strengths	Different formulations of the same active ingredient have different release characteristics	Salofalk	N/A	✓	N/A	Treatment for ulcerative colitis and Crohn's disease. There is no 'a' or 'b' flagging across the different brands of enteric tablets including Mesasal, Salofalk and Asacol.
mesalazine enteric tablet; available in 800 mg and 1.6 g strengths	Different formulations of the same active ingredient have different release characteristics	Asacol	N/A	✓	N/A	Treatment for ulcerative colitis. There is no 'a' or 'b' flagging across the different brands of enteric tablets including Mesasal, Salofalk and Asacol.
mesalazine 1.2 g modified release tablet	Different formulations of the same active ingredient have different release characteristics	Mezavant	Mesalazine-TAKEDA	✓	✓	Treatment for ulcerative colitis
mesalazine modified release granules; available in 1 g, 2 g and 4 g strengths	Different formulations of the same active ingredient have different release characteristics	Pentasa	N/A	✓	N/A	Supply only – not for new prescriptions. Treatment for ulcerative colitis and Crohn's disease. There is a lack of therapeutic equivalence in the treatment of ulcerative colitis between Pentasa and Salofalk brands of mesalazine modified release granules.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
mesalazine modified release granules; available in 500 mg, 1 g, 1.5 g and 3 g strengths	Different formulations of the same active ingredient have different release characteristics	Salofalk	N/A	✓	N/A	Treatment for ulcerative colitis. There is a lack of therapeutic equivalence in the treatment of ulcerative colitis between Pentasa and Salofalk brands of mesalazine modified release granules.
mesalazine 1g suppository	Different formulations of the same active ingredient have different release characteristics	Pentasa		✓	N/A	Treatment for ulcerative proctitis. There is no 'a' or 'b' flagging across the different brands of mesalazine suppository formulations
mesalazine 1g suppository	Different formulations of the same active ingredient have different release characteristics	Salofalk		✓	N/A	Treatment for ulcerative proctitis.
mesalazine 1 g enema	Different formulations of the same active ingredient have different release characteristics	Pentasa		✓	N/A	Treatment for ulcerative colitis. There is no 'a' or 'b' flagging across the different brands of mesalazine enema formulations
mesalazine 1 g/ application enema	Different formulations of the same active ingredient have different release characteristics	Salofalk Foam		✓	N/A	Treatment for ulcerative colitis.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
methylprednisolone 40 mg injection	Different formulations of the same active ingredient have different dosing and / or rates of administration	SOLU-medrol Act-O-Vial 40 mg injection [1 chamber] (&) inert substance diluent [1 mL chamber], 1 dual chamber vial	Methylpred 40 mg injection	✓	✓	<ul style="list-style-type: none"> <li>Intramuscular use for less than or equal to 250 mg dose only</li> <li>Intravenous use for all doses (administration times change).</li> </ul> <b>Caution: Specify brand to avoid confusion with methylprednisolone acetate formulations.</b>
methylprednisolone acetate 40 mg/mL modified release injection	Different formulations of the same active ingredient have different dosing and / or rates of administration	DEPO-medrol	Depo-Nisolone	✓	✓	Methylprednisolone acetate should not be administered by any route other than intramuscular, intra-articular, soft tissue or intralesional injection, and then for treatment of specific conditions or diseases. <b>Caution: Specify brand to avoid confusion with methylprednisolone formulations.</b>
methylprednisolone aceptonate 0.1% ointment	Different formulations of the same active ingredient have different dosing and / or rates of administration	Advantan	N/A	✓	N/A	The active ingredient of both Advantan Ointment and Advantan Fatty Ointment is the same – the ointment is suitable for dry, fissured, scaly or hyperkeratinised skin areas
methylprednisolone aceptonate 0.1% ointment	Different formulations of the same active ingredient have different dosing and / or rates of administration	Advantan Fatty	Tanilone	✓	✗	The active ingredient of both Advantan Ointment and Advantan Fatty Ointment is the same – the Fatty ointment has an occlusive effect and is indicated for psoriasis treatment areas where the stratum corneum is particularly thick, i.e. elbows, knees, palms, and soles

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
misoprostol 200 microgram tablet	Different formulations of the same active ingredient have different dosing	Cytotec	N/A	✗	N/A	-
misoprostol 200 microgram tablet	Different formulations of the same active ingredient have different dosing	Gymiso	N/A	✗	N/A	-
<b>morphine sulfate pentahydrate 10 mg tablet</b>	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Sevredol 10 mg tablet	N/A	✓	N/A	Morphine sulfate pentahydrate 10 mg tablets are an immediate release formulation. <b>Caution: Specify by brand to avoid confusion with modified release 10 mg capsules and tablets.</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
<b>morphine sulfate pentahydrate 10 mg</b> modified release capsule	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Kapanol 10 mg modified release capsule	N/A	✓	N/A	Morphine sulfate pentahydrate modified release capsules contain identical polymer-coated sustained-release pellets. The PI for MS Contin states ‘It is not possible to ensure bioequivalence between different brands of modified release morphine products. Caution is needed when changing between different brands of sustained or modified release morphine, or other strong opioid analgesic preparations, and the patient should be re-titrated and clinically re-assessed.’ <b>Caution: Specify by brand to avoid confusion with immediate release 10 mg tablets.</b>
<b>morphine sulfate pentahydrate 10 mg</b> modified release tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	MS Contin 10 mg modified release tablet	<ul style="list-style-type: none"> <li>• Morphine MR Apotex</li> <li>• Momex SR 10</li> <li>• Morphine MR AN</li> <li>• Morphine MR Mylan</li> </ul>	✓	✓	Morphine sulfate pentahydrate 10 mg modified release tablets are ‘a’ flagged on PBS with the generic brands and can be safely prescribed by active ingredient. <b>Caution: Specify by brand to avoid confusion with immediate release 10 mg tablets.</b>
<b>morphine sulfate pentahydrate 20 mg</b> tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Sevredol 20 mg tablet	N/A	✓	N/A	Morphine sulfate pentahydrate 20 mg tablets are an immediate release formulation. <b>Caution: Specify by brand to avoid confusion with modified release 20 mg capsules.</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
<b>morphine sulfate pentahydrate 20 mg</b> modified release capsule	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Kapanol 20 mg modified release capsule	N/A	✓	N/A	Kapanol (Morphine sulfate pentahydrate) capsules contain identical polymer-coated sustained-release pellets of the active ingredient. <b>Caution: Specify by brand to avoid confusion with immediate release 20 mg tablets.</b>
<b>morphine sulfate pentahydrate 30 mg</b> tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Anamorph 30 mg tablet	N/A	✓	N/A	Morphine sulfate pentahydrate 30 mg tablets are an immediate release formulation. <b>Caution: Specify by brand to avoid confusion with modified release 30 mg capsule and tablets.</b>
<b>morphine sulfate pentahydrate 30 mg</b> modified release capsule	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	MS Mono 30 mg modified release capsule	N/A	✓	N/A	<b>Caution: Specify by brand to avoid confusion with immediate release 30 mg tablets</b>



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
<b>morphine sulfate pentahydrate 30 mg</b> modified release tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	MS Contin 30 mg modified release tablet	<ul style="list-style-type: none"> <li>• Morphine MR Apotex</li> <li>• Morphine MR AN</li> <li>• Morphine MR Mylan</li> </ul>	✓	✓	Morphine sulfate pentahydrate 30 mg modified release tablets are 'a' flagged on PBS with the generic brands and can be safely prescribed by active ingredient. <b>Caution: Specify by brand to avoid confusion with immediate release 30 mg tablets.</b>
mycophenolate mofetil 250 mg capsule	Narrow therapeutic index (immunosuppress-ant)	CellCept 250 mg capsule	<ul style="list-style-type: none"> <li>• APO-Mycophenolate</li> <li>• Ceptolate</li> <li>• Mycophenolate Sandoz</li> <li>• Pharmacor Mycophenolate 250</li> <li>• Mycophenolate NLS</li> <li>• Alcept 250</li> <li>• MyAccord</li> <li>• Trancept</li> <li>• CellPlant</li> <li>• CelMuno</li> <li>• Imulate</li> </ul>	✓	✓	<ul style="list-style-type: none"> <li>• Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist</li> <li>• Mycophenolate NLS, Alcept 250, MyAccord, Trancept, CellPlant, CelMuno and Imulate are not PBS listed</li> </ul>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
mycophenolate mofetil 500 mg tablet	Narrow therapeutic index (immunosuppressant)	CellCept 500 mg tablet	<ul style="list-style-type: none"> <li>• APO-Mycophenolate</li> <li>• Ceptolate</li> <li>• MycoCept</li> <li>• Mycophenolate APOTEX</li> <li>• Mycophenolate GH</li> <li>• Mycophenolate SANDOZ</li> <li>• Pharmacor Mycophenolate 500</li> <li>• Aspen-Mycophenolate</li> <li>• MOFIT 500</li> <li>• Mytil</li> <li>• Mycokem 500</li> </ul>	✓	✓	<ul style="list-style-type: none"> <li>• Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist</li> <li>• Aspen-Mycophenolate, MOFIT 500, Mytil and Mycokem 500 are not PBS listed</li> </ul>
mycophenolate enteric tablet; available in 180 mg and 360 mg strengths	Narrow therapeutic index (immunosuppressant)	Myfortic	N/A	✓	N/A	For prophylaxis of renal allograft rejection – careful monitoring of patients is mandatory. Management includes initiation, stabilisation and review of therapy as required.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
Oral contraceptive pills	Similarity of active ingredient names will likely cause confusion and selection errors	There are many oral contraceptive products that include the same, or very similar, active ingredient names which could lead to prescribing, dispensing and administration errors	–	–	–	–
oxycodone hydrochloride 5 mg tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	Endone	<ul style="list-style-type: none"> <li>• Oxycodone Aspen</li> <li>• Mayne Pharma Oxycodone IR</li> </ul>	✓	✓	Oxycodone hydrochloride 5 mg tablet is an immediate release formulation. <b>Caution: Specify by brand to avoid confusion with modified release dose forms.</b>
oxycodone hydrochloride 10 mg capsule	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	oxyNORM 10 mg capsule	Oxycodone BNM	✓	✓	Oxycodone hydrochloride 10 mg capsule is an immediate release formulation. <b>Caution: Specify by brand to avoid confusion with modified release 10 mg tablet.</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
oxycodone hydrochloride 10 mg modified release tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	oxyCONTIN 10 mg modified release tablet	<ul style="list-style-type: none"> <li>Novacodone</li> <li>Oxycodone Sandoz</li> </ul>	✓	✓	Oxycodone hydrochloride 10 mg tablet is a modified release formulation. <b>Caution: Specify by brand to avoid confusion with immediate release 10 mg capsule.</b> Both OxyContin and Novacodone tablets are modified release tablets designed to provide delivery of oxycodone over 12 hours. They comprise a matrix formulation with a hydrogelling property intended to be crush-deterrent and to reduce the rapid release of oxycodone upon accidental or intentional misuse.
oxycodone hydrochloride 20 mg capsule	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	oxyNORM	Oxycodone BNM	✓	✓	Oxycodone hydrochloride 20 mg capsule is an immediate release formulation. <b>Caution: Specify by brand to avoid confusion with modified release 20 mg tablet.</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
oxycodone hydrochloride 20 mg modified release tablet	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (opioid analgesic)</b>	oxyCONTIN	<ul style="list-style-type: none"> <li>Novacodone</li> <li>Oxycodone Sandoz</li> </ul>	✓	✓	<p>Oxycodone hydrochloride 20 mg tablet is a modified release formulation.</p> <p><b>Caution: Specify by brand to avoid confusion with immediate release 20 mg capsule.</b> Both OxyContin and Novacodone tablets are modified release tablets designed to provide delivery of oxycodone over 12 hours. They comprise a matrix formulation with a hydrogelling property intended to be crush-deterrent and to reduce the rapid release of oxycodone upon accidental or intentional misuse.</p>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
PACLitaxel (as nanoparticle albumin-bound) powder for injection; available in 100 mg and 250 mg strengths	<p>Different formulations of the same active ingredient have different release characteristics.</p> <p>Different brands have different dosing regimens for different approved indications</p>	Abraxane	N/A	✓	N/A	<p>nanoparticle albumin-bound PACLitaxel (Abraxane) is indicated for:</p> <ul style="list-style-type: none"> <li>• Treatment of metastatic carcinoma of the breast after failure of anthracycline therapy</li> <li>• Non-small Cell Lung Cancer in combination with carboplatin</li> <li>• Metastatic adenocarcinoma of the Pancreas in combination with gemcitabine (<a href="#">see PI</a>)</li> <li>• Only the 100 mg strength of Abraxane is listed on the PBS</li> <li>• PACLitaxel is also available in a concentrated injection sterile solution (see PI) indicated for primary treatment of ovarian cancer in combination, treatment of metastatic ovarian cancer and metastatic breast cancer, and for the treatment of non-small cell lung cancer. The brands of PACLitaxel (NOT nanoparticle albumin bound) are interchangeable.</li> </ul>
paliperidone palmitate modified release injection, 1 syringe; available in 25 mg, 50 mg, 75 mg, 100 mg and 150 mg	<p>Different formulations of the same active ingredient have different release characteristics –</p> <p><b>High-risk medicine (antipsychotic)</b></p>	Invega Sustenna	N/A	✓	N/A	<p>Paliperidone modified release injection in 25 mg, 50 mg, 75 mg, 100 mg and 150 mg strengths for <b>1 month treatment</b> of schizophrenia. <b>Caution: Specify by brand to avoid confusion with Invega Trinza modified release injections.</b></p>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
paliperidone palmitate modified release injection, syringe; available in 175 mg/0.875 mL, 263 mg/1.315 mL, 350 mg/1.75 mL and 525 mg/2.625 mL	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (antipsychotic)</b>	Invega Trinza	N/A	✓	N/A	Paliperidone modified release injection in 175 mg, 263 mg, 350 mg, and 525 mg strengths for 3 months treatment of schizophrenia. <b>Caution: Specify by brand to avoid confusion with Invega Sustenna modified release injections.</b>
primidone 250 mg tablet	Narrow therapeutic index (anti-epileptic)	APO-Primidone	N/A	✓	N/A	There is no 'a' or 'b' flagging across both brands of primidone
primidone 250 mg tablet	Narrow therapeutic index (anti-epileptic)	Mysoline	N/A	✓	N/A	There is no 'a' or 'b' flagging across both brands of primidone
progesterone pessary; available in 100 mg and 200 mg strengths	Different brands have different dosing regimens for the same indication and are not assessed as therapeutically equivalent	Oripro	N/A	✓	N/A	–
progesterone 100 mg pessary	Different brands have different dosing regimens for the same indication and are not assessed as therapeutically equivalent	Endometrin	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
progesterone 200 mg pessary	Different brands have different dosing regimens for the same indication and are not assessed as therapeutically equivalent	Utrogestan	N/A	✓	N/A	–
quinine bisulfate heptahydrate 300 mg tablet	Similarity of active ingredient names will likely cause confusion and selection errors	Quinbusil	N/A	✗	N/A	Quinine bisulfate heptahydrate has 70% of the activity of quinine sulfate dehydrate. Appropriate dose adjustment required to achieve adequate dose for treatment.
quinine sulfate dihydrate 300 mg tablet	Similarity of active ingredient names will likely cause confusion and selection errors	Quinate	N/A	✓	N/A	–
salbutamol 100 microgram/ actuation inhalation	Delivery device continuity required	Airomir Autohaler	N/A	✓		An autohaler is a breath actuated inhaler, which automatically releases a metered dose, without the patient having to coordinate actuation with inspiration.
salbutamol 100 microgram/ actuation inhalation	Delivery device continuity required	Ventolin	<ul style="list-style-type: none"> <li>Asmol</li> <li>Zempreon</li> </ul>	✓	✓	Available as an inhaler (CFC-free) is a conventional press and breathe metered dose inhaler.



INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
somatrogon 24 mg/ 1.2 mL injection	Similarity of active ingredient name and strength will likely cause confusion and selection errors	Ngenia	N/A	✗	N/A	Somatrogon is a long-acting recombinant human growth hormone (rhGH) developed as once-weekly treatment for children with growth hormone deficiency (GHD).  Similarity of active ingredient name with somatropin 24 mg may cause confusion and selection errors
somatropin 400 microgram injection [1 chamber] (&) inert substance diluent [0.25 mL chamber]; also available in 600 microgram, 800 microgram, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg and 2 mg strengths where each active ingredient is supplied with an inert substance diluent in a dual chamber syringe	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	Genotropin MiniQuick	N/A	✓	N/A	There are many different brands of somatropin, which all come in different devices, formulations and presentations. Confusion in dosing could lead to adverse outcomes in children diagnosed with growth hormone deficiency.
somatropin 4 mg injection [1 vial] (&) inert substance diluent [1 vial]	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	Zomacton	N/A	✓	N/A	As of October 2021, Zomacton is no longer registered on the ARTG. However, Zomacton will be retained on the LMBC for reference.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
somatropin (recombinant human growth hormone) powder for injection 5 mg with diluent in pre-filled pen (with preservative), also available in 12 mg strength	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	Genotropin GoQuick	N/A	✓	N/A	–
somatropin injection; available in 5 mg/1.5 mL injection and 10 mg/1.5 mL injection strengths	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	<ul style="list-style-type: none"> <li>• Norditropin FlexPro</li> <li>• SciTropin A</li> <li>• Omnitrope Surepal 5</li> <li>• Omnitrope Surepal 10</li> </ul>	N/A	✓	N/A	–
somatropin 6 mg injection [1 cartridge] (& inert substance diluent [3.15 mL syringe], also available in 12 mg and 24 mg strengths	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics.  Similarity of active ingredient name and strength	Humatrope	N/A	✓	N/A	Similarity of active ingredient name and strength to somatrogron 24 mg may cause confusion and selection errors.

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
somatropin 10 mg/2 mL injection, 2 mL cartridge	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	NutropinAq	N/A	✓	N/A	–
somatropin injection; available in 6 mg/1.03 mL injection, 12 mg/1.5 mL injection and 20 mg/2.5 mL injection strengths	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	Saizen	N/A	✓	N/A	–
somatropin 15 mg/1.5 mL injection	Different formulations of the same active ingredient have different dosing and / or rates of administration and / or release characteristics	<ul style="list-style-type: none"> <li>• Norditropin FlexPro</li> <li>• Omnitrope Surepal 15</li> </ul>	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
TACrolimus capsule; available in 500 microgram, 1 mg and 5 mg strengths	Narrow therapeutic index	Prograf	<ul style="list-style-type: none"> <li>• Pacrolim</li> <li>• Pharmacor TACrolimus</li> <li>• TACrolimus Apotex</li> <li>• Tacrograf</li> <li>• TACrolimus Sandoz</li> </ul>	✓	✓	Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist. All immediate release capsule formulations of TACrolimus at 500 microgram, 1 mg, and 5 mg strengths are 'a' flagged on PBS.
TACrolimus modified release capsule; available in 500 microgram, 1 mg, 3 mg and 5 mg strengths	Narrow therapeutic index	Advagraf XL	N/A	✓	N/A	–
theophylline 133.3 mg/25 mL oral liquid	Narrow therapeutic index	Nuelin	N/A	✓	N/A	–
theophylline modified release tablet; available in 200 mg, 250 mg and 300 mg strengths	Narrow therapeutic index	<ul style="list-style-type: none"> <li>• Nuelin-SR 200</li> <li>• Nuelin-SR 250</li> <li>• Nuelin-SR 300</li> </ul>	N/A	✓	N/A	–
timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Timoptol XE	N/A	✓	N/A	Treatment for glaucoma

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
timolol 0.5% eye drops	Similarity of active ingredient names will likely cause confusion and selection errors	Timoptol	N/A	✓	N/A	Treatment for glaucoma
tolvaptan tablet; available in 15 mg and 30 mg strengths	Different formulations of the same active ingredient have different dosing	Jinarc	N/A	✓	N/A	-
tolvaptan tablet; available in 15 mg and 30 mg strengths	Different formulations of the same active ingredient have different dosing	Samsca	N/A	✓	✗	-
tRAMadol 50 mg modified release tablet	Narrow therapeutic index – <b>High-risk medicine (opioid)</b>	Tramal SR 50	N/A	✓	N/A	tRAMadol hydrochloride modified release tablets are 'a' flagged on PBS with the generic brands and can be safely prescribed by active ingredient for the 100 mg, 150 mg, and 200 mg strengths. However the 50 mg modified release tablet is only available under the Tramal SR 50 brand. <b>Caution is required when prescribing tRAMadol 50 mg strength as both modified release tablets (Tramal SR) and immediate release capsules (Tramal) are available under the Tramal brand.</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
tRAMadol 50 mg capsule	Narrow therapeutic index – <b>High-risk medicine (opioid)</b>	Tramal	<ul style="list-style-type: none"> <li>• Zydol</li> <li>• APO-tRAMadol</li> <li>• Chemmart tRAMadol</li> <li>• Terry White Chemists tRAMadol</li> <li>• tRAMadol AMNEAL</li> <li>• tRAMadol AN</li> <li>• tRAMadol SCP</li> <li>• tRAMadol Sandoz</li> <li>• Tramedo</li> </ul>	✓	✓	<ul style="list-style-type: none"> <li>• tRAMadol hydrochloride immediate release capsules are ‘a’ flagged on PBS with the generic brands and can be safely prescribed by active ingredient. <b>Caution is required when prescribing tRAMadol 50 mg strength as both modified release tablets (Tramal SR) and immediate release capsules (Tramal) are available under the Tramal brand.</b></li> <li>• Chemmart tRAMadol and Terry White Chemists tRAMadol are not PBS listed</li> </ul>
trastuzumab 60 mg injection	Similarity of active ingredient names will likely cause confusion and selection errors	Herceptin	Trazimera	✗	✓	Treatment for metastatic (Stage IV) HER2 positive breast cancer. <b>Caution: Potential for confusion between an antibody and antibody-medicine conjugate.</b>
trastuzumab 150 mg injection	Similarity of active ingredient names will likely cause confusion and selection errors	Herceptin	<ul style="list-style-type: none"> <li>• <b>Ogivri</b></li> <li>• Herzuma</li> <li>• Kanjinti</li> <li>• Ontruzant</li> <li>• Trazimera</li> </ul>	✗	✓	Treatment for metastatic (Stage IV) HER2 positive breast cancer. <b>Caution: Potential for confusion between an antibody and antibody-medicine conjugate.</b>
trastuzumab 420 mg injection	Similarity of active ingredient names will likely cause confusion and selection errors	Kanjinti	N/A	✓	✓	Treatment for metastatic (Stage IV) HER2 positive breast cancer. <b>Caution: Potential for confusion between an antibody and antibody-medicine conjugate. Caution: 420 mg injection only available in originator / reference brand.</b>

INN (active ingredient name)	Principle	Originator / reference brand	Generic / biosimilar brand	Originator / reference brand PBS listed	Generic / biosimilar brand PBS listed	Notes
trastuzumab emtasine injection; available in 100 mg and 160 mg strengths	Similarity of active ingredient names will likely cause confusion and selection errors	Kadcyla	N/A	✓	N/A	Potential for confusion between an antibody and antibody-medicine conjugate
warfarin 1 mg, 2 mg and 5 mg tablet	Not therapeutically equivalent	coUMADIN	N/A	✓	N/A	There is no 'a' or 'b' flagging across both brands of warfarin
warfarin 1 mg, 3 mg and 5 mg tablet	Not therapeutically equivalent	Marevan	N/A	✓	N/A	There is no 'a' or 'b' flagging across both brands of warfarin
zuclopenthixol acetate injection; available in 50 mg/mL and 100 mg/2 mL strengths	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (antipsychotic)</b>	Clopixol Acuphase	N/A	✗	N/A	Initial treatment of acute psychoses, mania and exacerbation of chronic psychoses
zuclopenthixol decanoate 200 mg/mL injection	Different formulations of the same active ingredient have different release characteristics – <b>High-risk medicine (antipsychotic)</b>	Clopixol Depot	N/A	✓	N/A	Maintenance treatment of acute psychoses, mania and exacerbation of chronic psychoses. May be an advantage in the treatment of noncompliant patients.

## AUSTRALIAN COMMISSION ON SAFETY AND QUALITY IN HEALTH CARE

Level 5, 255 Elizabeth Street, Sydney NSW 2000  
GPO Box 5480, Sydney NSW 2001

Phone: (02) 9126 3600

Email: [mail@safetyandquality.gov.au](mailto:mail@safetyandquality.gov.au)

Website: [www.safetyandquality.gov.au](http://www.safetyandquality.gov.au)